Across TCGA pan-cancer cohorts, TMEM222 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TMEM222 data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TMEM222 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM222 expression acts as an unfavorable survival marker.

LIHC, SKCM, and ACC are the cancer types where TMEM222 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.070	0.544	<.001	15	view →
SKCM	DFS	Median	II,III,IV	0.188	0.712	.003	8	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: TMEM222 tumor-vs-normal RNA expression · all TMEM222 data types